Navigation Links
Huntington's disease discovery provides new hope for treatment
Date:7/28/2010

Australian scientists have identified the behaviour of the mutant protein 'huntingtin' which leads to the fatal Huntington's disease providing potential targets to treat the disease, a University of Melbourne study reveals.

Huntington's disease is a genetic disease with no cure, characterized by a steady decline in motor control and the dysfunction and death of brain cells. The cause of the disease has long baffled scientists.

Symptoms tend to first appear when the person is in their thirties or forties. The most common symptom is jerky movements of the arms and legs. A person with Huntington's disease may also have difficulties with speech, swallowing and concentration.

Using state of the art technology, Dr Danny Hatters and his colleagues at the University of Melbourne's Department of Biochemistry and Molecular Biology at the Bio 21 Institute observed how human mutant 'huntingtin' proteins form into large clumps, which kills brain cells and leads to progressed Huntington's disease.

"Steps prior to the clustering of the mutated proteins were thought to damage cells, but these steps were not clearly detectable under a microscope," Dr Hatters says.

"Understanding this process and finding the right target to block the ultimate death of the brain cells has been extremely difficult to determine," he says.

The technology called analytical ultracentrifugation and the methodology the researchers developed enabled them to visualize this process in much greater detail.

"What we have shown and are the first to show, is that mutated huntingtin protein forms three different sized clusters in the damaged cells," he says.

"This discovery will help to develop a targeted treatment that shuts down the key processes causing the clusters to form and for the disease to progress."

While researchers previously thought that small clusters of the mutant protein kept accumulating over time until they overwhelmed and killed the brain cells, Dr Hatters' team found that these clusters were static, which means they form in a more unpredictable manner than previously thought.

The discovery reveals the clusters place a steady stress on cells over time rather than steadily building up over time to some critical "toxic" level as previously thought.

"Why it takes so long for the cells to die in human disease is not known - however it could be that cells eventually cannot compensate anymore from the process where toxicity is built up to form one cluster called oligomers," he says.

"The real key of our work is that we now have direct targets in the critical steps in the process of cell toxicity and death and to gauge any therapeutic effects of drugs on these targets. We can also measure how this alleviates cellular toxicity and brain cell death.'

"Importantly our research techniques could have application in assisting to find drug targets for other neurodegenerative diseases where toxic clusters of proteins play a role in the progression of the disease, such as for Parkinson's disease."


'/>"/>

Contact: Rebecca Scott
rebeccas@unimelb.edu.au
61-383-440-181
University of Melbourne
Source:Eurekalert

Related biology news :

1. UM researcher identifies novel treatment for pain in sickle cell disease
2. U of T researchers find link between childhood physical abuse and heart disease
3. Protein important in diabetes may also play a key role in heart disease, other disorders
4. Research results confirm need for protection against ticks that carry Lyme disease
5. Dairy farmers can fight growing disease threat with chlorine and stainless steel
6. Disease genes that followed the Silk Road identified
7. Scientists discover clues to inflammatory disease
8. Waterborne diseases could cost over $500 million annually in US
9. Plavix may be treatment for dogs at risk of thromboembolic disease
10. Modulator of fetal hemoglobin switch may target sickle cell disease
11. Mount Sinai researchers discover new way diseases develop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology: